Clinical and microbiological determinants of infection after transrectal prostate biopsy

Clinical Infectious Diseases

Volumn 60, Issue 7, 2015, Pages 979-987

  Liss, Michael A ^a,b   Johnson, James R ^c   Porter, Stephen B ^c   Johnston, Brian ^c   Clabots, Connie ^c   Gillis, Kyle ^b   Nseyo, Unwanaobong ^b   Holden, Marc ^b   Sakamoto, Kyoko ^a,b   Fierer, Joshua ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Rady Children's Specialists of San Diego   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

antibiotic resistance; biopsy; infection; prostate

Indexed keywords

AMIKACIN; AMPICILLIN; AZTREONAM; CEFAZOLIN; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; ERTAPENEM; GENTAMICIN; IMIPENEM; MEROPENEM; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; TOBRAMYCIN; QUINOLONE DERIVATIVE;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; HUMAN; INFECTION RATE; INFECTIOUS COMPLICATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR TYPING; NONHUMAN; OBSERVATIONAL STUDY; POSTTRANSRECTAL PROSTATE BIOPSY INFECTION; PRIORITY JOURNAL; PROSTATE BIOPSY; TRANSRECTAL PROSTATE BIOPSY; URINARY TRACT INFECTION; URINE CULTURE; ADVERSE EFFECTS; BIOPSY; CALIFORNIA; CLASSIFICATION; COHORT ANALYSIS; ESCHERICHIA COLI INFECTIONS; GENETICS; GENOTYPE; ISOLATION AND PURIFICATION; MICROBIOLOGY; MOLECULAR EPIDEMIOLOGY; PROSTATITIS; PUBLIC HOSPITAL; RECTUM; RISK FACTOR;

AGED; BIOPSY; CALIFORNIA; COHORT STUDIES; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FLUOROQUINOLONES; GENOTYPE; HOSPITALS, VETERANS; HUMANS; MALE; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; MOLECULAR TYPING; PROSTATITIS; RECTUM; RISK FACTORS;

EID: 84926625721     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu1129     Document Type: Article

References (23)

1. Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61: 1079-92.
2. Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data from SEER-Medicare. J Urol 2011; 186: 1830-4.
3. Nam RK, Saskin R, Lee Y, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 2010; 183:963-8.
4. Williamson DA, Barrett LK, Rogers BA, Freeman JT, Hadway P, Paterson DL. Infectious complications following transrectal ultrasoundguided prostate biopsy: new challenges in the era of multidrug-resistant Escherichia coli. Clin Infect Dis 2013; 57:267-74.
5. Loeb S, Vellekoop A, Ahmed HU, et al. Systematic review of complications of prostate biopsy. Eur Urol 2013; 64:876-92.
6. Johnson JR, Porter SB, Zhanel G, Kuskowski MA, Denamur E. Virulence of Escherichia coli clinical isolates in a murine sepsis model in relation to sequence type ST131 status, fluoroquinolone resistance, and virulence genotype. Infect Immun 2012; 80:1554-62.
7. Lopez-Cerero L, Navarro MD, Bellido M, et al. Escherichia coli belonging to the worldwide emerging epidemic clonal group O25b/ST131: risk factors and clinical implications. J Antimicrob Chemother 2014; 69:809-14.
8. Lavigne JP, Vergunst AC, Goret L, et al. Virulence potential and genomic mapping of the worldwide clone Escherichia coli ST131. PLoS One 2012; 7:e34294.
9. Hillelsohn JH, Duty B, Blute ML Jr, et al. Variability of transrectal ultrasound-guided prostate biopsy prophylactic measures. Can J Urol 2012; 19:6573-7.
10. Grummet JP, Weerakoon M, Huang S, et al. Sepsis and 'superbugs': should we favour the transperineal over the transrectal approach for prostate biopsy?. BJU Int 2014; 114:384-8.
11. Duplessis CA, Bavaro M, Simons MP, et al. Rectal cultures before transrectal ultrasound-guided prostate biopsy reduce post-prostatic biopsy infection rates. Urology 2012; 79:556-61.
12. Suwantarat N, Dumford DM III, Ponce-Terashima R, et al. Modification of antimicrobial prophylaxis based on rectal culture results to prevent fluoroquinolone-resistant Escherichia coli infections after prostate biopsy. Infect Control Hosp Epidemiol 2013; 34:973-6.
13. Taylor AK, Zembower TR, Nadler RB, et al. Targeted antimicrobial prophylaxis using rectal swab cultures in men undergoing transrectal ultrasound guided prostate biopsy is associated with reduced incidence of postoperative infectious complications and cost of care. J Urol 2012; 187:1275-9.
14. Batura D, Rao GG, Nielsen PB. Prevalence of antimicrobial resistance in intestinal flora of patients undergoing prostatic biopsy: implications for prophylaxis and treatment of infections after biopsy. BJU Int 2010; 106:1017-20.
15. Clinical and Laboratory Standards Institute . Performance standards for antimicrobial susceptibility testing: 20th informational supplement M100-S20. Wayne, PA: CLSI, 2010.
16. Johnson JR, Menard M, Johnston B, Kuskowski MA, Nichol K, Zhanel GG. Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004. Antimicrob Agents Chemother 2009; 53:2733-9.
17. Banerjee R, Robicsek A, Kuskowski MA, et al. Molecular epidemiology of Escherichia coli sequence type 131 and Its H30 and H30-Rx subclones among extended-spectrum-beta-lactamase-positive and-negative E. coli clinical isolates from the Chicago region, 2007 to 2010. Antimicrob Agents Chemother 2013; 57:6385-8.
18. Colpan A, Johnston B, Porter S, et al. Escherichia coli sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among US veterans. Clin Infect Dis 2013; 57:1256-65.
19. Rogers BA, Sidjabat HE, Paterson DL. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-Associated strain. J Antimicrob Chemother 2011; 66:1-14.
20. Nicolas-Chanoine MH, Bertrand X, Madec JY. Escherichia coli ST131, an intriguing clonal group. Clin Microbiol Rev 2014; 27:543-74.
21. Lindert KA, Kabalin JN, Terris MK. Bacteremia and bacteriuria after transrectal ultrasound guided prostate biopsy. J Urol 2000; 164:76-80.
22. Aron M, Rajeev TP, Gupta NP. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU Int 2000; 85:682-5.
23. Liss MA, Nakamura KK, Meuleners R, Kolla SB, Dash A, Peterson EM. Screening rectal culture to identify fluoroquinolone-resistant organisms before transrectal prostate biopsy: do the culture results between office visit and biopsy correlate?. Urology 2013; 82:67-71.